Waters, BD biosciences unit agree to $17.5 billion merger
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Celecoxib is a nonsteroidal anti-inflammatory drug
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated